IP Library Granted Patent US 7,972,602
Granted Patent B2
US 7,972,602 · App. 11/836,645 · Granted Jul 5, 2011

Promiscuous HER-2/Neu CD4 T cell epitopes

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,972,602
App. No.
11/836,645
Granted
Jul 5, 2011
Kind
B2
Abstract

The present invention relates to the discovery of novel T cell epitopes of the human HER-2/Neu protein that is promiscuous for at least 25 different HLA-DR alleles. The invention also relates to compositions that contain one of the novel epitopes or a fusion peptide of such a epitope and a heterologous polypeptide. Further disclosed herein is the use of the epitopes or their fusion peptides, and compositions containing the epitopes or their fusion peptides.

Claims (15)

1. An isolated peptide consisting of the amino acid sequence of SEQ ID NOS:2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 31.

2. The peptide of claim 1 , which consists of the amino acid sequence of SEQ ID NOS:20, 21, 22, or 23.

3. The peptide of claim 1 , which consists of the amino acid sequence of SEQ ID NOS:24, 25, or 26.

4. The peptide of claim 1 , which consists of the amino acid sequence of SEQ ID NOS:27, 28, 29, or 31.

5. The peptide of claim 1 , which has the amino acid sequence of SEQ ID NO:2.

6. A fusion peptide comprising the peptide of claim 1 fused to a heterologous polypeptide.

7. The fusion peptide of claim 6 , wherein the peptide of claim 1 is fused to a heterologous polypeptide via a peptide bond.

8. The fusion peptide of claim 6 , wherein the heterologous polypeptide is a granulocyte-macrophage colony-stimulating factor (GM-CSF).

9. A composition comprising the peptide of claim 1 or the fusion peptide of claim 2 and a physiologically acceptable excipient.

10. The composition of claim 9 , wherein the peptide has the amino acid sequence of SEQ ID NO:2.

11. The composition of claim 9 , wherein the heterologous polypeptide is a granulocyte-macrophage colony-stimulating factor (GM-CSF).

12. The composition of claim 9 , further comprising an antigen-presenting cell with the peptide of claim 1 forming a complex with a major histocompatibility complex (MHC) molecule on the surface of the cell.

13. The composition of claim 9 , wherein the peptide consists of the amino acid sequence of SEQ ID NOS:20, 21, 22, or 23.

14. The composition of claim 9 , wherein the peptide consists of the amino acid sequence of SEQ ID NOS:24, 25, or 26.

15. The composition of claim 9 , wherein the peptide consists of the amino acid sequence of SEQ ID NOS:27, 28, 29, or 31.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED AT REEL: 042389 FRAME: 505. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded Feb 14, 2018
From: DENDREON PHARMACEUTICALS, INC.
To: DENDREON PHARMACEUTICALS LLC
Reel/Frame 046088/0882 →
RELEASE OF SECURITY INTEREST Recorded Jul 5, 2017
From: BARCLAYS BANK PLC
To: DENDREON PHARMACEUTICALS LLC
Reel/Frame 043089/0288 →
CHANGE OF NAME Recorded May 3, 2017
From: DENDREON PHARMACEUTICALS, INC.
To: DENDREON PHARMACEUTICALS LLC
Reel/Frame 042389/0505 →